Jump to start of content

Complete requirements by 12/31/19 to avoid a change in certification status Expand/Collapse the ABIM alert.

Sign in to your Physician Portal to view any remaining requirements for the year. Not completing these requirements by 12/31/19 could result in a change to your certification status.

Breadcrumb trail:

Hematology Board Exam Committee

Expand All | Collapse All

Anne T. Neff, MD, Chair

Anne T. Neff, MD, ChairDr. Neff is currently a staff physician in Benign Hematology at the Cleveland Clinic Hospitals' Department of Hematology/Medical Oncology. She is board certified in Internal Medicine, Hematology, Blood Banking and Transfusion Medicine.

Previously, Dr. Neff was a Professor of Medicine, Pathology, Microbiology and Immunology at Vanderbilt University. There she also served as Director of the Hemostasis & Thrombosis Clinic, Director of Transfusion Medicine and was the founding Director of the stem cell collection program.

Dr. Neff has served on national committees for the American Association of Blood Banks including Chair of the Scientific Section of the Annual Program Planning committee, Standards Committee for Blood Banks and Transfusion Services, and Standards for Cellular Therapy Products. She has served on the American Society of Hematology's (ASH) Transfusion Scientific Committee and as a speaker at the Highlights of ASH programs in 2014. She was elected to serve on the Board of Directors for the Hemophilia and Thrombosis Research Society from 2008 to 2011. Additionally, Dr. Neff is Chair of the American Board of Internal Medicine Hematology Board Exam Committee.

Dr. Neff earned her bachelor's degree in psychology at the University of Missouri-Columbia, where she also graduated with her medical degree and trained in internal medicine. She did her fellowship training in hematology at Vanderbilt University.

As of April 2019, Dr. Neff reported the following external relationships:

Service on a research-related expert panel or advisory board for the following companies, with compensation for travel expenses and honoraria:

  • Genentech, for advising on hemophilia inhibitors.
  • Novo Nordisk, for advising on hemophilia A treatment.

Kristie A. Blum, MD

Kristie A. Blum, MDDr. Blum is an Associate Professor in the Division of Hematology and Section Head of the Lymphoma Program at The Ohio State University. She is board certified in Hematology and Medical Oncology with expertise and extensive experience in the clinical development of novel therapeutics for patients with aggressive B-cell non-Hodgkin (NHL) and Hodgkin's lymphoma (HL).

Dr. Blum has been a faculty member at The Ohio State University since 2003, as an Associate Professor from 2010 to 2015 and as an Assistant Professor from 2003 to 2010.

Dr. Blum was the Associate Director of the Hematology/Oncology Fellowship Program from 2005-2008 and the Director of the Hematology/Oncology Fellowship from 2008-2013. Stepping down from her fellowship role, she led The Ohio State University Lymphoma Clinical and Research Programs in 2013. Dr. Blum also serves on the American Board of Internal Medicine Hematology Board Exam Committee, the Lymphoma Research Foundation Scientific Advisory Board, the Alliance Co-Operative Group Lymphoma Committee, the American Society of Hematology Clinical Research Mentoring Program, and the National Comprehensive Cancer Network Hodgkin's Lymphoma Panel. She has directed and chaired the first Lymphoma Research Foundation Clinical Research Mentoring Program.

Dr. Blum has experience in the design, conduct and publication of phase I-II trials, with focused interest in drug development in lymphomas. She has been involved in several high-impact pharmaceutical trials including trials with lenalidomide, ibrutinib, brentuximab and idelalisib that have led to FDA approvals of several of these agents.

Dr. Blum earned her medical degree at the University of Miami. She completed internal medicine residency from 1997 to 2000 at University of Virginia, her hematology/oncology fellowship training at Vanderbilt University from 2000 to 2001 and Washington University in St. Louis from 2001 to 2003.

As of February 2019, Dr. Blum reported the following external relationships:

Funding for clinical trial expenses, staff, and salary support, paid to The Ohio State University, from the following companies:

  • Bristol-Myers Squibb
  • Genentech
  • Janssen
  • TG Therapeutics

Dr. Blum serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American Society for Hematology, Clinical Research Training Institute Oversight Committee, receiving reimbursement for travel expenses and honoraria.
  • Alliance for Clinical Trials in Oncology, Alliance Lymphoma Committee, Cadre Member, receiving reimbursement for travel expenses.
  • Lymphoma Research Foundation, Scientific Advisory Board; LRF Clinical Research Mentoring Program, Chair, receiving reimbursement for travel expenses.

Kelly M. Davidson, MD

Kelly M. Davidson, MDDr. Davidson is an Assistant Professor of Medicine in the Division of Hematology and Oncology at the University of Virginia (UVA), where she practices hematology at the Emily Couric Clinical Cancer Center. She was initially certified in internal medicine, medical oncology and hematology, and maintains her certification in hematology.

Dr. Davidson specializes in a variety of benign and malignant hematologic diseases, with a focus on cellular hematology. She sees patients with myeloproliferative and myelodysplastic disorders, red cell disorders including sickle cell disease, bone marrow failure syndromes, plasma cell dyscrasias, mast cell disorders and disorders of hemostasis and thrombosis. In addition to clinical practice, Dr. Davidson teaches in the second-year medical student course in hematology and plays an active role in resident and fellowship training at UVA. She previously practiced both hematology and oncology at Associates in Oncology/Hematology in Rockville, Maryland.

From 2015 through present, Dr. Davidson has been named to the list of Best Doctors in America. In 2016, she served on the American Board of Internal Medicine (ABIM) Standard Setting Panel for the Hematology Maintenance of Certification Exam (ABIM), and currently serves as a member of the ABIM Hematology Board Exam Committee. She has been a member of the American Society of Hematology since 2003.

Dr. Davidson received a biology degree summa cum laude from Georgetown University and her medical degree from Washington University in St. Louis. She completed internship and residency in internal medicine at Beth Israel Deaconess Medical Center in Boston and fellowship training in hematology and oncology at UVA.

As of April 2019, Dr. Davidson reported no external relationships.

Chancellor E. Donald, MD

Chancellor E. Donald, MDDr. Donald currently practices at Lourdes Oncology Associates in Lafayette, Louisiana. In 2010, he joined the practice and became Managing Partner in 2014. Additionally, at Our Lady of Lourdes Regional Medical Center, he functions as Medical Director of the oncology service line, a member of the Medical Executive Committee and as a Trustee on the Board of Directors.

Dr. Donald is board certified in Internal Medicine, Hematology and Medical Oncology. He serves on the American Board of Internal Medicine’s Hematology Exam Board Committee.

Dr. Donald advocates for patients with malignancies and hematologic disorders. He is currently President of the Louisiana Oncology Society. He has been appointed to the Board of Directors of the Community Oncology Alliance. In 2013, he was given the Spirit of Hope Award by the American Cancer Society. The American Society of Hematology (ASH) selected him for its Committee on Practice. He also holds the position of ASH’s alternate delegate to the American Medical Association’s House of Delegates. Since 2012, he has served as the Hematology Representative for Louisiana for the Medicare Carrier Advisory Committee (CAC). He served as co-chair of the 2017 annual CAC meeting at the American Society of Clinical Oncology headquarters and was again selected for that role for the 2018 annual meeting at the American Society of Hematology headquarters. For the 2017 Annual Meeting of the American Society of Hematology, he served as the clinical designee to the Program Committee.

Dr. Donald graduated magna cum laude from Florida A&M University and received his medical degree from the University of Miami School of Medicine. He completed his internship, residency and fellowship at Tulane University. He served as Chief Resident and Chief Fellow there and currently holds the position of Clinical Assistant Professor within Tulane’s Department of Hematology/Oncology.

As of May 2019, Dr. Donald reported the following external relationships:

Service on a research-related expert panel or advisory board for the following companies, receiving honoraria:

  • Pfizer, for serving on an advisory board discussing the sequencing and use of tyrosine kinase inhibitors for epidermal growth factor receptor-mutated lung cancer.
  • Puma Biotechnology, for serving on an advisory board to discuss the interpretation of data obtained from clinical trials for neratinib.

Dr. Donald serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American Society of Hematology, Standing Member of Committee on Practice; Alternate Delegate to the House of Delegates of the American Medical Association; receiving reimbursement for travel expenses.
  • Community Oncology Alliance, Board of Directors, Member, without compensation.
  • Taking Aim at Cancer in Louisiana Initiative, Chief Medical Officer, without compensation. Louisiana Oncology Society, Immediate Past President, without compensation.

Morie A. Gertz, MD

Morie A. Gertz, MDDr. Gertz is the Roland Seidler Jr. Professor of the Art of Medicine and Chair of the Department of Medicine at the Mayo Clinic. He is board certified in Internal Medicine, Hematology and Medical Oncology.

Previously, Dr. Gertz served as Treasurer for the International Myeloma Society and as President of Mayo Staff Officers and Councilors. He was the Chair of the Mayo Personnel Committee. He currently serves on the American Society of Hematology Training Program Committee and the American Board of Internal Medicine Hematology Board Exam Committee.

He has been recognized with the 2014 Jan Waldenström Medal for Medical and Scientific Achievements in Waldenström's Macroglobulinemia and is a Mayo Distinguished Clinician. He has been recognized for his contributions in amyloidosis and Waldenström's macroglobulinemia. He has authored more than 500 peer-reviewed publications in the field and is a frequently invited speaker nationally.

Dr. Gertz is a master of the American College of Physicians. His undergraduate degree was awarded with highest distinction from Northwestern University, graduating Phi Beta Kappa. He received his medical degree cum laude from Loyola Medical School and was elected to Alpha Omega Alpha, the medical honor society. He completed a three-year medical residency at Rush Presbyterian St. Luke's Hospital in Chicago and was voted Resident of the Year for two of those years.

As of February 2019, Dr. Gertz reported the following external relationships:

Preclinical research, with funding for staff provided to the Mayo Clinic, from the following company:

  • Annexon Biosciences, for patient sera for antibody testing.

Funding for clinical trial expenses and staff, from the following companies:

  • Alnylam, for a trial of imRNA for familial amyloidosis, providing funding for staff, paid to Mayo Clinic.
  • Ionis, for a trial of IRNA for familial amyloidosis, providing funding for staff and expenses.
  • Millennium for a trial of bortezomib for amyloidosis AL, providing funding for staff, paid to Mayo Clinic.
  • Pfizer Pharmaceuticals, for a trial of tafamidis for cardiac amyloidosis, providing funding for staff, paid to Mayo Clinic.

Attendance at investigators' meetings, with compensation as listed from the following companies:

  • Millennium, to discuss a strategic planning model, receiving reimbursement for travel expenses and honoraria.
  • Novartis, for sales force education, receiving reimbursement for travel expenses and honoraria.
  • Onyx, receiving reimbursement for travel expenses and honoraria.

Service on data and safety monitoring boards for the following company, with honoraria:

  • AbbVie, for a Phase III trial of venetoclax.

Service on research-related expert panel or advisory board for the following company, with compensation as listed:

  • Celgene, to advise on medical content of lectures sponsored by the company, receiving reimbursement for travel expenses and honoraria.
  • Sandoz, to advise on use of biosimilars, receiving honoraria.

Industry-supported continuing medical education supported by the following, with compensation as listed:

  • Onyx, receiving reimbursement for travel expenses and honoraria.

Teaching in industry-sponsored satellite symposia with funding from the following company, with compensation as

  • Research to Practice, a medical education company that receives support from pharmaceutical companies, receiving reimbursement for travel expenses and honoraria.

Dr. Gertz serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • BMJ Point of Care, receiving compensation for creating online content.

Dr. Gertz serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American Society of Hematology, Training Committee, receiving reimbursement for travel expenses.
  • Amyloidosis Support Network, receiving reimbursement for travel and other expenses associated with providing lectures to patients.
  • International Waldenstroms Macroglobulinemia Foundation receiving reimbursement for travel and other expenses associated with providing lectures to patients.

Elizabeth Hexner, MD

Elizabeth Hexner, MDDr. Hexner is a physician scientist with an interest in education and two major research interests in malignant hematology: the first is in cellular therapies and hematopoietic stem cell transplantation, and the second is in myeloproliferative neoplasms (MPN). Both have a translational focus and align with my clinical roles as Medical Director of the Center for Cellular Immunotherapies and as Director of the Penn MPN program. In MPN I have designed and executed preclinical studies of JAK inhibitors and also used bioassays and correlative studies in MPN patients treated with JAK inhibitors focused on resistance.

Her work in MPN, cellular therapies, stem cell transplantation, primary cell systems and preclinical and clinical investigation allows me to intersect productively with basic science, transfusion medicine, regulatory, and clinical colleagues. In another major area of focus I serve as the Associate Director of the NIH CTSA-funded Masters in Translational Research program at the University of Pennsylvania, serving on the education, selection, and curriculum committees and overseeing a cohort of candidates as a programmatic mentor.

As of July 2019, Dr. Hexner reported the following external relationships:

Funding for clinical trial expenses, salary support and staff, paid to the University of Pennsylvania, from the following companies:

  • Blueprint Medicines, receiving funding for staff and expenses.
  • TMUNITY, receiving funding for salary support.

Cindy A. Leissinger, MD

Dr. Leissinger is Professor of Medicine and Clinical Professor of Pediatrics and Pathology at Tulane University in New Orleans, Louisiana, and is Chief of the Hematology/Oncology Division there. She became Director of the Louisiana Comprehensive Hemophilia Care Center (now the Louisiana Center for Bleeding and Clotting Disorders) in 1992, and has remained in that position ever since. She is board certified in Internal Medicine and Hematology.

In addition to caring for patients with bleeding and clotting disorders, Dr. Leissinger oversees an active research program. She participates in several clinical research groups, and has been an active investigator for many research studies related to bleeding disorders, with a particular interest in Factor VIII inhibitor development and management.

Dr. Leissinger is a member of the American Board of Internal Medicine Hematology Board Exam Committee. Additionally, she is actively involved in the American Society of Hematology, the International Society on Thrombosis and Haemostasis, and the Hemostasis and Thrombosis Research Society.

Dr. Leissinger received her medical degree from Tulane University School of Medicine. She completed a residency in internal medicine at Tulane, a research fellowship in hematology at the National Institutes of Health in Bethesda, Maryland, and a clinical fellowship in hematology and medical oncology at Tulane.

As of April 2019, Dr. Leissinger reported the following external relationships:

Funding for clinical trial expenses and staff, paid to Tulane University, from the following companies:

  • Biomarin, for a study of a FVIII gene therapy.
  • Roche, for a study of a new Factor VIII mimetic protein.

Industry-supported continuing medical education supported by the following, with compensation for travel expenses and honoraria:

  • Genentech, for general educational talks on hemophilia.

Dr. Leissinger serves in a significant role with the following organization:

  • Hemostasis and Thrombosis Research Society, President-Elect, receiving no compensation.

Dr. Lessinger also reported that she serves on advisory boards for the following pharmaceutical companies, and receive honoraria for participation in advisory board meetings that are focused on bleeding disorders, mainly hemophilia and Von Willebrand disease: Takeda, Bayer, CSL Behring, Kedrion, Roche (Genentech), HemaBiologics, Uniqure, Spark Therapeutics.

Robert T. Means Jr., MD

Robert T. Means Jr., MDDr. Means, a board certified internist and hematologist, is Dean and Professor of Internal Medicine at the James H. Quillen College of Medicine, East Tennessee State University in Johnson City, Tennessee.

Before coming to Quillen, he was Executive Dean of the University of Kentucky College of Medicine. Other positions Dr. Means held at Kentucky included Senior Associate Chair of Internal Medicine, Interim Director of the Markey Cancer Center and Chief of the Medical Service at the Lexington VA Medical Center. He served as Director of the Hematology Oncology Division at the Medical University of South Carolina, and was on faculty at the University of Cincinnati and Vanderbilt.

Dr. Means is a member of the American Board of Internal Medicine Hematology Board Exam Committee. He is past President of the Southern Society for Clinical Investigation and a Fellow of the American College of Physicians. He is also an Associate Editor of the Journal of Investigative Medicine, and serves on editorial boards for the American Journal of the Medical Sciences, Blood Research, and International Journal of Hematology. He is on the Medical & Scientific Advisory Board of the Iron Disorders Institute.

Dr. Means received his bachelor's degree in biochemistry from Rice University in Houston, Texas. He earned his medical degree at Vanderbilt University in Nashville, Tennessee. He trained in internal medicine at Baylor College of Medicine Affiliated Hospitals in Houston, Texas, before returning to Vanderbilt for a fellowship in hematology.

As of February 2019, Dr. Means reported the following external relationships:

Work as an author or editor for following companies, with compensation as listed:

  • Lippincott Williams Wilkins/Wolters Kluwer, receiving royalties for the textbook, Wintrobe's Clinical Hematology, 12th and 13th editions.
  • Springer, receiving compensation as an editor for Anemia in the Young and Old: Diagnosis and Management.

Dr. Means serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • Southern Society for Clinical Investigation, Executive Advisory Committee, compensation for lodging at annual retreat provided directly to hotel.
  • Iron Disorders Institute, Member of the Medical & Scientific Advisory Board, without compensation.

Laura C. Michaelis, MD

Laura C. Michaelis, MDDr. Michaelis is an Associate Professor of Medicine at the Medical College of Wisconsin. She is the Associate Vice Chair of the Department of Medicine and serves as the Director of Inpatient Services for the Division of Hematology/Oncology. She is board certified in Hematology and her professional interests include clinical research in acute and chronic leukemias.

Previously, Dr. Michaelis was the director of the fellowship program at Loyola University Medical Center, where she worked as a general hematologist for seven years after finishing her fellowship. While practicing at Loyola, Dr. Michaelis became interested in physician-patient education and advocacy as well as peer-to-peer education. She co-chaired the Chicago MPN roundtable, an organization devoted to teaching patients and practitioners about the standard of care in this rare condition.

Dr. Michaelis is active in the American Society of Hematology, where she serves on the publications committee and communications committee and is the editor-in-chief of The Hematologist. She also serves on the Educational Committee for the Society of Hematologic Oncology and also serves on the American Board of Internal Medicine Hematology Board Exam Committee. She is a member of the ASH guidelines committee on leukemia in the elderly and continues to participate actively in patient-education forums, speaking nationally on myeloproliferative disorders to patient groups.

Dr. Michaelis did her fellowship in hematology and oncology at the University of Chicago and completed her internship and residency in internal medicine at the Brigham and Women’s Hospital in Boston. She graduated from Harvard Medical School in 2000. Before entering medical school, Dr. Michaelis was a newspaper and magazine reporter. She earned a Master of Journalism degree from Northwestern University and worked at news outlets throughout the country, including the MacNeill-Lehrer NewsHour, the Los Angeles Times and Congressional Quarterly.

As of April 2019, Dr. Michaelis reported the following external relationships:

Funding for clinical trial expenses, salary support and staff, paid to Medical College of Wisconsin, from the following company:

  • Jazz, to receive funding for clinical trial staff, expenses, and salary support that will soon begin.

Work as an author or editor for following company, with compensation as listed:

  • American Society of Hematology, Editor-in-chief for The Hematologist, receiving honoraria and reimbursement for travel expenses.

Dr. Michaelis serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • American Society of Hematology, Speaker at national meeting, receiving reimbursement for travel expenses and honoraria.